Topical PTSD Drug Poised for Human Trials.
In a press release issued on February 15, Psycheceutical Bioscience (BWVI), in partnership with iNGENū, a contract research organization in the cannabinoid and psychedelic...
Adding Psycheceutical Bioscience (BWVI) $0.14 to Watch List. Ketamine.
Above: Lamar Odom and Psychedelic Spokesman Mike Zappy Zapolin
We're Calling a Sector Bottom, and Psycheceutical (BWVI) as Our Favorite.
We launched the Psychedelic Stock Review...
Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment...
Topline Results anticipated by the end of Q2 2023
CRANFORD, N.J. , April 3, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced...
Citius Pharma (CTXR). Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update
$36.9 million in cash and cash equivalents as of December 31, 2022 ; runway through February 2024
Uptick in patient recruitment for Mino-Lok® Phase 3 trial
Halo-Lido Phase 2b trial nearing completion
CRANFORD,...
Adding Cardiol Therapeutics (CRDL) $0.59 to Watch List.
Adding to 2023 Biotech Stock Review Watch List. We Think This One Has Legs.
Starting Due Diligence Now.
It takes us about 15 minutes after talking...
Ardelyx (ARDX) Resubmits New Drug Application to FDA.
WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize...
And we Have Another Triple! Ardelyx (ARDX) Touches $5.00, up 333%.
LIVE QUOTE
Ardelyx Enters the Danger Zone* With Tenapanor.
The company produced favorable (albeit very technical) information (data) at the National Kidney Foundation 2023 Spring Clinical...
Unicycive Therapeutics (UNCY) $2.73 Tacks on Another 30%. We’re now up 249%.
Stormin..Live Quote
We're still not sure how to pronounce it...but Wall Street likes it.
News Archive
Unicycive Therapeutics (UNCY) $2.73. We're now up 249%.
Unicycive (UNCY) Shoots and...
Latest article
Jeffrey Gundlach: Reckoning is Coming.
Jeffrey Edward Gundlach is a businessman, fund manager, and philanthropist. He is the founder of DoubleLine Capital, an investment firm.
On 11 November 2020, Gundlach remarked in an interview with...
Who’s the Next Eric Sprott?
Eric Sprott, on Who is the Next Eric Sprott!
To say Eric Sprott has left a legendary mark on the world of mining investment would...
Perpetua (PPTA) Raises $300 Million.
Not a bad day in Idaho. $300 million banked! We look at the dip as a buying opportunity, as does John Paulson & Co.,...
